We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Elevated Metal Ion Level Detects Defective Hip Arthroplasty Implants

By LabMedica International staff writers
Posted on 26 May 2020
Total hip replacement (THR) has proven to be a highly effective treatment of degenerative joint disease. More...
Hip replacement implants can be made of different metallic alloys according to their specific properties and the related clinical need.

Metal ions from these alloys will be systematically released due to the bearing wear, taper junction wear/corrosion or passive surface corrosion. Performance of each implant can be assessed indirectly by measuring systemic ion levels in whole blood.

Medical Laboratory Scientists at the Maisonneuve-Rosemont Hospital (Montreal, QC, Canada) collected 71 whole blood samples were collected from 64 patients with unilateral ceramic-on-ceramic hip arthroplasty. For each patient, two whole blood samples were collected and analyzed in two different laboratories.

The investigators analyzed 71 pairs of whole blood samples from 64 patients. Patient’s mean age at time of surgery was 54 years old (range 33–73; ± 9.2), 26 men and 38 women. In one laboratory the concentrations of titanium (Ti), Chromium-cobalt (Cr and Co) ions in whole blood samples were measured with a single quadrupole ICP-MS Elan DRCII (PerkinElmer, Waltham, MA, USA). The detection limits were 0.1 μg/L for Cr and 0.035 μg/L for Co. In the other laboratory the concentrations of Ti, Cr and Co ions in the whole blood samples were measured in an Element 2 High Resolution, Sector-Field, Inductively Coupled Plasma Mass Spectrophotometer (HR-ICP-MS, Thermo Fisher Scientific GmBH, Bremen, Germany). The detection limits were 0.1 μg/L for Cr and 0.02 μg/L for Co.

The scientists reported that the for distributions of Ti concentrations from the two laboratories there was no distinction for the direction of the difference in Ti concentration (minus or positive) since 100% of results from laboratory 1 were higher than laboratory 2. The concentrations obtained from laboratory 1 are significantly different from those of laboratory 2. The average ratio between laboratories (#1 divided by #2) is 4.10 (range 1–20.76). In 69% of cases the difference was above 300%, and in 39% above 500%. The team found that 64/71 (90%) of paired samples had an absolute difference above the predetermined threshold of 1 μg/L. A mean variation ratio of 410% between the two laboratories was found.

The authors concluded that metal ions blood screening is a common way of detecting mal-functioning orthopedic implants. However, all laboratories do not use the same technologies or calibrations to do these measurements. Different laboratories leading to a significant risk of misinterpretation can measure clinically significant level difference. Therefore, clinical decision should not rely on a single measurement made by one laboratory. The study was published on May 8, 2020 in the journal Practical Laboratory Medicine.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.